Critical Considerations of Residual CV Risk in Patients With T2D & ASCVD
A Treatment for NYHA Class II-III Obstructive HCM Patients
Strategies for CV Risk Reduction in Complex T2D Patients
ASCVD Risk Reduction in Patients With T2D
Joshua Stolker, MD
PeerThe ASCVD Journey With Lp(a): An ApoB-Family Lipoprotein
Understanding Lp(a): Clinical Implications of an Underrecognized Genetic Dyslipidemia
Santica Marcovina, PhD, ScD
PeerLetters From the Heart: People Should Know About Lp(a)
Keys to Helping Overcome the Growing Prevalence of Peripheral Artery Disease
Research Updates on Postprandial Dyslipidemia Treatment
Alan S. Brown, MD, FACC, FAHA, FNLA
PeerWhat is HoFH: Detection and Management of the Homozygous Familial Hypercholesterolemia (HoFH) Patient
Alan S. Brown, MD, FACC, FAHA, FNLA
Peer